New multilocus sequence typing scheme for Enterococcus faecium reveals sequential outbreaks of vancomycin-resistant E. faecium ST1162 and ST610 in a Japanese tertiary medical center
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.02131-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Masaki Karino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory and Biomedical Sciences, Laboratory of Medical Microbiology and Microbiome, Division of Health Sciences, Osaka Univ…. Hauptthemen laut MEDLINE: Multilocus Sequence Typing, Enterococcus faecium, Disease Outbreaks, Vancomycin-Resistant Enterococci. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Borderless Design Medical Research Center, MEXT | Japan Society for the Promotion of Science (JSPS), Yakult Bio-Science Foundation (YBSF).
Abstract (Originalsprache)
Vancomycin-resistant Enterococcus faecium (VREfm) is a major nosocomial pathogen, and molecular epidemiological tools are crucial for controlling its spread. Pulsed-field gel electrophoresis (PFGE) is still used in clinical laboratories despite the increased accessibility of whole-genome sequencing (WGS). As PFGE equipment is no longer commercially available, clinical laboratories need alternative tools. Highly standardized multilocus sequence typing (MLST) is one option. However, the original MLST scheme for E. faecium , designed in 2002, showed inconsistencies with WGS-based typing. Therefore, the new Bezdíček MLST scheme, which offers more accurate genetic similarity based on genome-wide data, has recently been proposed. To clarify its clinical utility in analyzing nosocomial VREfm transmission, we compared both MLST schemes with PFGE using 68 VREfm isolates collected during an outbreak at a Japanese tertiary medical center in 2019. PFGE analysis identified nine clusters among the 68 strains, including two predominant clusters. The original scheme identified five sequence types (ST O s), of which 82.4% (56/68) were ST O 192. The Bezdíček scheme identified nine sequence types (ST B s), subdividing the original ST O 192 into ST B 1162 (30/56), ST B 610 (25/56), and ST B 895 (1/56). Simpson’s index of diversity values were 0.635, 0.317, and 0.648 for PFGE, the original scheme, and the Bezdíček scheme, respectively. Combining the Bezdíček scheme with admission records provided clearer outbreak visualization, indicating that two distinct ST B s independently caused sequential outbreaks. With high discriminatory power comparable with PFGE and global availability, the Bezdíček scheme is a practical and valuable tool for controlling nosocomial VREfm infections in clinical laboratories. IMPORTANCE In areas where vancomycin-resistant Enterococcus faecium is common, hospital-acquired infections pose a considerable threat to patients’ lives owing to treatment difficulties. Although whole-genome sequencing-based typing has logically become the new reference standard and its accessibility is growing, many clinical laboratories still lack the fundamental resources to exploit its full potential. Limited availability of the traditional pulsed-field gel electrophoresis test in clinical settings has necessitated the use of alternative tools such as Bezdíček multilocus sequence typing. This study tested the clinical utility of the Bezdíček scheme by comparing it with pulsed-field gel electrophoresis. Designed using Czech isolates, this scheme showed comparable discriminatory powers with the traditional method for geographically distinct Japanese isolates and clearly visualized outbreaks. These findings suggest that the Bezdíček scheme is a potential alternative to pulsed-field gel electrophoresis for identifying hospital transmission of vancomycin-resistant Enterococcus faecium in clinical laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory and Biomedical Sciences, Laboratory of Medical Microbiology and Microbiome, Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Clinical Laboratory, Rinku General Medical Center, Izumisano, Osaka, Japan.
- Department of Medical Technology, Faculty of Health Sciences, Kansai University of Health Sciences, Sennan-gun, Osaka, Japan.
- Division of Microbiology, Osaka Institute of Public Health, Osaka, Japan.
- Departments of General Internal Medicine and Infectious Diseases, Rinku General Medical Center, Izumisano, Osaka, Japan.
ORCID-Profile: Masaki Karino, Masashi Yanagihara, Tetsuya Harada, Hirofumi Ohtaki, Shigefumi Okamoto
Förderung
- Borderless Design Medical Research Center
- MEXT | Japan Society for the Promotion of Science (JSPS)
- Yakult Bio-Science Foundation (YBSF)
Zitieren
APA
Karino, M., Yanagihara, M., Harada, T., Sugo, M., Karino, M., Ohtaki, H., Hanada, H., Takano, T., Yamato, M., & Okamoto, S. (2025). New multilocus sequence typing scheme for Enterococcus faecium reveals sequential outbreaks of vancomycin-resistant E. faecium ST1162 and ST610 in a Japanese tertiary medical center. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02131-24
Vancouver
Karino M, Yanagihara M, Harada T, Sugo M, Karino M, Ohtaki H, et al. New multilocus sequence typing scheme for Enterococcus faecium reveals sequential outbreaks of vancomycin-resistant E. faecium ST1162 and ST610 in a Japanese tertiary medical center. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02131-24
BibTeX
@article{Karino2025,
author = {Karino, Masaki and Yanagihara, Masashi and Harada, Tetsuya and Sugo, Megumi and Karino, Mizuki and Ohtaki, Hirofumi and Hanada, Hiroyuki and Takano, Toru and Yamato, Masaya and Okamoto, Shigefumi},
title = {New multilocus sequence typing scheme for Enterococcus faecium reveals sequential outbreaks of vancomycin-resistant E. faecium ST1162 and ST610 in a Japanese tertiary medical center},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.02131-24}
}
EUVIMED